Home › Multiple Myeloma › Michigan › Detroit
Multiple Myeloma clinical trials in Detroit, MI
19 studies for Multiple Myeloma are looking for participants at sites in and around Detroit (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Karmanos Cancer Institute, Detroit
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
RecruitingPhase 3
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
- Barbara Ann Karmanos Cancer Institute, Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- Henry Ford Health Saint John Hospital, Detroit
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
RecruitingPhase 3
- Henry Ford Health System, Detroit
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecruitingPhase 3
- Henry Ford Health Saint John Hospital, Detroit
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
RecruitingPhase 1/2
- Karmanos Cancer Institute, Detroit
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecruitingPhase 1/2
- Research Site, Detroit
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecruitingPhase 3
- Research Site, Detroit
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
- Karmanos Cancer Institute, Detroit
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RecruitingPhase 1
- Karmanos Cancer Institute, Detroit
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RecruitingPhase 4
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
RecruitingPhase 2
- Karmanos Cancer Institute, Detroit
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecruitingPhase 3
- Ascension Saint John Hospital, Detroit
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RecruitingPhase 1
- Karmanos Cancer Institute, Detroit
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RecruitingPhase 1/2
- Karmanos Cancer Institute, Detroit
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RecruitingPhase 3
- GSK Investigational Site, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Recruiting
- Karmanos Cancer Institute, Detroit
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
Other studies in Detroit
- Non-Small Cell Lung Cancer44 studies
- Breast Cancer33 studies
- Cancer (all types)29 studies
- Colorectal Cancer26 studies
- Ovarian Cancer26 studies
- Metastatic Cancer24 studies
- Prostate Cancer22 studies
- Endometrial Cancer21 studies
- Lung Cancer20 studies
- Stomach Cancer16 studies
- Head and Neck Squamous Cell Carcinoma15 studies
- Acute Myeloid Leukemia14 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.